Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France
Abstract Background The risk of severe COVID-19 and its determinants remain largely unknown in patients with autoimmune and inflammatory rheumatic diseases. The objective of this study was to assess the prevalence of COVID-19 infection in patients followed for rare autoimmune diseases as well as the...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-021-02565-0 |
id |
doaj-b65b877ec5674d6bac810b5e6b32599f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Renaud Felten Marc Scherlinger Aurélien Guffroy Vincent Poindron Alain Meyer Margherita Giannini Anne-Sophie Korganow Christelle Sordet Emmanuel Chatelus Rose-Marie Javier Aurore Meyer Luc Pijnenburg Jean-François Kleinmann Jacques-Eric Gottenberg Jean Sibilia Thierry Martin Laurent Arnaud |
spellingShingle |
Renaud Felten Marc Scherlinger Aurélien Guffroy Vincent Poindron Alain Meyer Margherita Giannini Anne-Sophie Korganow Christelle Sordet Emmanuel Chatelus Rose-Marie Javier Aurore Meyer Luc Pijnenburg Jean-François Kleinmann Jacques-Eric Gottenberg Jean Sibilia Thierry Martin Laurent Arnaud Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France Arthritis Research & Therapy Autoimmune diseases Epidemiology Immune system diseases COVID-19 |
author_facet |
Renaud Felten Marc Scherlinger Aurélien Guffroy Vincent Poindron Alain Meyer Margherita Giannini Anne-Sophie Korganow Christelle Sordet Emmanuel Chatelus Rose-Marie Javier Aurore Meyer Luc Pijnenburg Jean-François Kleinmann Jacques-Eric Gottenberg Jean Sibilia Thierry Martin Laurent Arnaud |
author_sort |
Renaud Felten |
title |
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France |
title_short |
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France |
title_full |
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France |
title_fullStr |
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France |
title_full_unstemmed |
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France |
title_sort |
incidence and predictors of covid-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in france |
publisher |
BMC |
series |
Arthritis Research & Therapy |
issn |
1478-6362 |
publishDate |
2021-07-01 |
description |
Abstract Background The risk of severe COVID-19 and its determinants remain largely unknown in patients with autoimmune and inflammatory rheumatic diseases. The objective of this study was to assess the prevalence of COVID-19 infection in patients followed for rare autoimmune diseases as well as the predictors of COVID-19 and disease flare-ups. Methods Cross-sectional phone survey from April 9, 2020, to July 2, 2020, during which patients with autoimmune diseases followed at the National Reference Center for Rare Autoimmune diseases of Strasbourg were systematically contacted by phone and sent a prescription for a SARS-CoV-2 serology. Results One thousand two hundred thirty-two patients were contacted. One thousand fifty-five patients with a confirmed diagnosis of systemic autoimmune disease were included (4 unreachable, 4 moves abroad, 5 deaths before pandemic, 50 without consent, and 114 without autoimmune disease). Among them, 469 (44.5%) patients were tested for SARS-CoV-2 serology. Thirty-nine patients (7.9%) had SARS-CoV-2 infection (either through chest CT-scan [n = 5], RT-PCR on nasopharyngeal swab [n = 14], or serology [n = 31]) among the 496 who underwent at least one of those 3 diagnosis modalities. Of the 39 proven cases, 33 had clinical manifestations (6 asymptomatic patients were diagnosed through systematic serology testing), 31 were managed by home care, 3 were hospitalized due to a need for oxygenation, two required admission to an intensive care unit, and one died. Among patients with confirmed SARS-CoV-2 infection, reported flares were more frequent than in uninfected patients (26.3% [10/38] vs. 7.0% [32/457], p < 0.0001). Preventive sick leave had no significant impact on the prevalence of SARS-CoV-2 infection (5.8% [3/53]) compared to work continuation (7.6% [30/397], p = 0.64). Overall, the seroprevalence of SARS-CoV-2 was 6.6% (31/469) which was numerically lower to the Grand-Est general population estimated to be 9.0%. Conclusions This systematic survey of more than 1000 patients with rare systemic autoimmune diseases reports a low prevalence of proven SARS-CoV-2 infection and very rare severe infections, probably related to good compliance with prophylactic measures in these patients. |
topic |
Autoimmune diseases Epidemiology Immune system diseases COVID-19 |
url |
https://doi.org/10.1186/s13075-021-02565-0 |
work_keys_str_mv |
AT renaudfelten incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT marcscherlinger incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT aurelienguffroy incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT vincentpoindron incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT alainmeyer incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT margheritagiannini incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT annesophiekorganow incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT christellesordet incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT emmanuelchatelus incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT rosemariejavier incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT auroremeyer incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT lucpijnenburg incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT jeanfrancoiskleinmann incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT jacquesericgottenberg incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT jeansibilia incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT thierrymartin incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance AT laurentarnaud incidenceandpredictorsofcovid19andflaresinpatientswithrareautoimmunediseasesasystematicsurveyandserologicalstudyatanationalreferencecenterinfrance |
_version_ |
1721296487592230912 |
spelling |
doaj-b65b877ec5674d6bac810b5e6b32599f2021-07-18T11:05:34ZengBMCArthritis Research & Therapy1478-63622021-07-012311910.1186/s13075-021-02565-0Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in FranceRenaud Felten0Marc Scherlinger1Aurélien Guffroy2Vincent Poindron3Alain Meyer4Margherita Giannini5Anne-Sophie Korganow6Christelle Sordet7Emmanuel Chatelus8Rose-Marie Javier9Aurore Meyer10Luc Pijnenburg11Jean-François Kleinmann12Jacques-Eric Gottenberg13Jean Sibilia14Thierry Martin15Laurent Arnaud16Service de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgService de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgCentre National de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest (RESO)Centre National de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest (RESO)Service de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgCentre National de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest (RESO)Centre National de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest (RESO)Service de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgService de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgService de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgCentre National de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest (RESO)Service de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgService de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgService de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgService de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgCentre National de Référence des Maladies Auto-Immunes Systémiques Rares Est Sud-Ouest (RESO)Service de rhumatologie, Service de rhumatologie, Hôpitaux Universitaires de Strasbourg et Université de StrasbourgAbstract Background The risk of severe COVID-19 and its determinants remain largely unknown in patients with autoimmune and inflammatory rheumatic diseases. The objective of this study was to assess the prevalence of COVID-19 infection in patients followed for rare autoimmune diseases as well as the predictors of COVID-19 and disease flare-ups. Methods Cross-sectional phone survey from April 9, 2020, to July 2, 2020, during which patients with autoimmune diseases followed at the National Reference Center for Rare Autoimmune diseases of Strasbourg were systematically contacted by phone and sent a prescription for a SARS-CoV-2 serology. Results One thousand two hundred thirty-two patients were contacted. One thousand fifty-five patients with a confirmed diagnosis of systemic autoimmune disease were included (4 unreachable, 4 moves abroad, 5 deaths before pandemic, 50 without consent, and 114 without autoimmune disease). Among them, 469 (44.5%) patients were tested for SARS-CoV-2 serology. Thirty-nine patients (7.9%) had SARS-CoV-2 infection (either through chest CT-scan [n = 5], RT-PCR on nasopharyngeal swab [n = 14], or serology [n = 31]) among the 496 who underwent at least one of those 3 diagnosis modalities. Of the 39 proven cases, 33 had clinical manifestations (6 asymptomatic patients were diagnosed through systematic serology testing), 31 were managed by home care, 3 were hospitalized due to a need for oxygenation, two required admission to an intensive care unit, and one died. Among patients with confirmed SARS-CoV-2 infection, reported flares were more frequent than in uninfected patients (26.3% [10/38] vs. 7.0% [32/457], p < 0.0001). Preventive sick leave had no significant impact on the prevalence of SARS-CoV-2 infection (5.8% [3/53]) compared to work continuation (7.6% [30/397], p = 0.64). Overall, the seroprevalence of SARS-CoV-2 was 6.6% (31/469) which was numerically lower to the Grand-Est general population estimated to be 9.0%. Conclusions This systematic survey of more than 1000 patients with rare systemic autoimmune diseases reports a low prevalence of proven SARS-CoV-2 infection and very rare severe infections, probably related to good compliance with prophylactic measures in these patients.https://doi.org/10.1186/s13075-021-02565-0Autoimmune diseasesEpidemiologyImmune system diseasesCOVID-19 |